Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815007 | 1.00 | EPHX2 (0.59) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL15595143 | 1.00 | EPHX2 (0.59) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL26696840 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL24096964 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL382915 | 0.86 | EPHX2 (0.52) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL19968080 | 0.84 | GAA (0.49) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL4988935 | 0.84 | GAA (0.49) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL452060 | 0.83 | GAA (0.54) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL7097599 | 0.81 | BTK (0.51) | EPHX2GAANFKB1NFKB2RELA | |
| SCHEMBL8325782 | 0.81 | BTK (0.51) | EPHX2GAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4058452-B1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240417387-A1 | SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4436667-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118076594-A | Sulfonylpiperazinyl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2017075056-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016198342-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | ABL1, Q6ZSR9, NQO2 | EPHX2 3544/4885GAA 2644/4885NFKB1 407/4885 |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | EPHX2 753/4885GAA 147/4885NFKB1 3263/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | EPHX2 2498/4885GAA 2710/4885NFKB1 652/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | EPHX2 2403/4885GAA 905/4885NFKB1 1952/4885 |
| US-20240417387-A1 | SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | CFTR, KCNQ1, Q6ZSR9 | EPHX2 4009/4885GAA 1560/4885NFKB1 2013/4885 |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | EPHX2 1915/4885GAA 4820/4885NFKB1 1335/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | EPHX2 1915/4885GAA 4820/4885NFKB1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.